CRISPR-Based Diagnostic Platform for Rapid Detection of Multidrug-Resistant Tuberculosis

Authors

  • Golob S Department of Molecular Biology, University of Maribor, Maribor, Slovenia Author
  • Schuster J Department of Microbiology, University of Hamburg, Hamburg, Germany Author
  • Iglesias N Department of Biotechnology, University of Salamanca, Salamanca, Spain Author

DOI:

https://doi.org/10.5281/zenodo.22638300

Keywords:

CRISPR-Cas diagnostics, multidrug-resistant tuberculosis, Mycobacterium tuberculosis detection, rifampicin resistance rpoB, isothermal amplification

Abstract

Background: Multidrug-resistant tuberculosis (MDR-TB) demands diagnostics that combine rapid Mycobacterium tuberculosis
(Mtb) detection with resistance genotyping. Objective: This narrative review synthesizes published evidence on
CRISPR-Cas-based platforms (Cas12a, Cas12b, Cas13a, Cas14a) for Mtb detection and rpoB/katG/inhA resistance-mutation
genotyping, benchmarked against Xpert MTB/RIF(Ultra) and line-probe assays. Methods: Peer-reviewed primary studies,
systematic reviews, and meta-analyses reporting analytical or clinical performance of CRISPR-based TB assays were identified
and synthesized narratively. Findings: Across assays, pooled CRISPR-based Mtb detection sensitivity and specificity reached 93%
and 97%, respectively, with drug-resistance genotyping sensitivity and specificity of 96% and 100%; a recent point-of-care
sputum assay reported 100% sensitivity and specificity against culture, with limits of detection near 69-81 CFU/mL, comparable to
Xpert Ultra. Conclusions: CRISPR-Cas diagnostics can match nucleic-acid-amplification-test accuracy for Mtb detection and
resistance genotyping using simpler isothermal chemistry, though larger multicenter validation, guide-RNA panel
standardization, and reagent-stability studies are needed before widespread programmatic adoption.

References

World Health Organization (2024). Global Tuberculosis Report 2024. WHO, Geneva. (Estimated 400,000 incident MDR/RR-TB cases in 2023, 95% UI 360,000-440,000.)

Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. (2010). Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine, 363(11), 1005-1015. DOI: 10.1056/NEJMoa0907847.

Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, et al. (2018). Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infectious Diseases, 18(1), 76-84. DOI: 10.1016/S1473-3099(17)30691-6.

Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, et al. (2021). Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database of Systematic Reviews, 2021(5), CD009593. DOI: 10.1002/14651858.CD009593.pub5.

Hillemann D, Rusch-Gerdes S, Richter E (2007). Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. Journal of Clinical Microbiology, 45(8), 2635-2640. DOI: 10.1128/JCM.00521-07.

Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, et al. (2017). Nucleic acid detection with CRISPR-Cas13a/C2c2. Science, 356(6336), 438-442. DOI: 10.1126/science.aam9321.

Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F (2018). Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science, 360(6387), 439-444. DOI: 10.1126/science.aaq0179.

Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, Doudna JA (2018). CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science, 360(6387), 436-439. DOI: 10.1126/science.aar6245.

Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F (2019). SHERLOCK: nucleic acid detection with CRISPR nucleases. Nature Protocols, 14(10), 2986-3012. DOI:

1038/s41596-019-0210-2. 10. Ai JW, Zhou X, Xu T, Yang M, Chen Y, He GQ, et al. (2019). CRISPR-based rapid and ultra-sensitive diagnostic test for Mycobacterium tuberculosis. Emerging Microbes & Infections, 8(1), 1361-1369. DOI: 10.1080/22221751.2019.1664939.

Sam IK, Chen YY, Ma J, Li SY, Ying RY, Li LX, et al. (2021). TB-QUICK: CRISPR-Cas12b-assisted rapid and sensitive detection of Mycobacterium tuberculosis. Journal of Infection, 83(1), 54-60. DOI: 10.1016/j.jinf.2021.04.032.

Yang X, Huang J, Chen Y, Ying X, Tan Q, Chen X, et al. (2023). Development of CRISPR/Cas12b-based multiple cross displacement amplification technique for the detection of Mycobacterium tuberculosis complex in clinical settings. Microbiology Spectrum, 11(2), e03475-22. DOI: 10.1128/spectrum.03475-22.

Peng L, Fang T, Cai Q, Li H, Li H, Sun H, et al. (2024). Rapid detection of Mycobacterium tuberculosis in sputum using CRISPR-Cas12b combined with cross-priming amplification in a single reaction. Journal of Clinical Microbiology, 62(1), e00923-23. DOI: 10.1128/jcm.00923-23.

Ren W, Zhou Y, Li H, Shang Y, Zhang X, Yuan J, et al. (2023). Development and clinical evaluation of CRISPR/Cas13a-based diagnostic test to detect Mycobacterium tuberculosis in clinical specimens. Frontiers in Microbiology, 14, 1117085. DOI: 10.3389/fmicb.2023.1117085.

Xiao J, Li J, Quan S, Wang Y, Jiang G, Wang Y, et al. (2023). Development and preliminary assessment of CRISPR-Cas12a-based multiplex detection of Mycobacterium tuberculosis complex. Frontiers in Bioengineering and Biotechnology, 11, 1233353. DOI: 10.3389/fbioe.2023.1233353.

Gan T, Yu J, Deng Z, He J (2024). ERA-CRISPR/Cas12a system: a rapid, highly sensitive and specific assay for Mycobacterium tuberculosis. Frontiers in Cellular and Infection Microbiology, 14, 1454076. DOI: 10.3389/fcimb.2024.1454076.

Huang Z, Song Z, Zeng J, Liu X, Fang M, Wu Z, et al. (2025). Sensitive pathogen DNA detection by a multi-guide RNA Cas12a assay favoring trans- versus cis-cleavage. Nature Communications, 16(1), 8257. 10.1038/s41467-025-63094-x.

Wu G, Ren Y, Wang Y, Zhao Y, Wu Y, Sun H, et al. (2025). Detection of rifampin-resistant Mycobacterium tuberculosis using CRISPR/Cas14a-enabled molecular techniques. BMC Infectious Diseases, 25(1), 1813. 10.1186/s12879-025-12190-w.

Abavisani M, Karbas Foroushan S, Khayami R, Sahebkar A (2024). Mycobacterium tuberculosis detection using CRISPR technology: an updated systematic review and meta-analysis. Molecular Diagnosis & Therapy, 28(6), 777-790. DOI: 10.1007/s40291-024-00741-x.

Bell AG, Dunkley ORS, Modi NH, Huang Y, Tseng S, Reiss R, et al. (2025). A streamlined CRISPR-based test for tuberculosis detection directly from sputum. Science Advances, 11(32), eadx2067. DOI: 10.1126/sciadv.adx2067.

Liu P, Zhang J, Gong Y, Liu W, Xiao G, Liang J, et al. (2025). Application of engineered CRISPR/Cas12a variants with altered protospacer adjacent motif specificities for the detection of isoniazid resistance mutations Mycobacterium tuberculosis. Microbiology Spectrum, 13(10), e00165-25. DOI: 10.1128/spectrum.00165-25.

Wulandari DA, Liwaissunati Zein MIH, Zakiyyah SN, Ishmayana S, Ozsoz M, Hartati YW, Irkham (2025). CRISPR-Cas9-based electrochemical biosensor for detection of katG gene mutations in isoniazid-resistant tuberculosis. ADMET and DMPK, 13(3), 2766. 10.5599/admet.2766.

Lin Z, Song Z, Yu H, Zhou Y, Liu D, Zhang P, et al. (2025). Ultra-sensitive in situ detection of intracellular Mycobacterium tuberculosis with CRISPR/Cas12a. Frontiers in Immunology, 16, 1597654. 10.3389/fimmu.2025.1597654.

Zein-Eddine R, Refregier G, Cervantes J, Yokobori NK (2023). The future of CRISPR in Mycobacterium tuberculosis infection. Journal of Biomedical Science, 30(1), 34. DOI: 10.1186/s12929-023-00932-4.

Shi L, Gu R, Long J, Duan G, Yang H (2024). Application of CRISPR-Cas-based technology for the identification of tuberculosis, drug discovery and vaccine development. Molecular Biology Reports, 51(1), 466. 10.1007/s11033-024-09424-6. a

Akkoul N, Kumar T, Sharma S, Sharma V, Raja V, Malik TG, Wan Mohd Jaafar WS, Gupta AK, Hakeem KR (2026). CRISPR-Cas-based detection of Mycobacterium tuberculosis: current advances and translational bottlenecks. Protoplasma. DOI: 10.1007/s00709-026-02250-6. a DOI: DOI: in the DOI: DOI: DOI:

Downloads

Published

2026-06-27